financetom
Business
financetom
/
Business
/
Bombardier's quarterly revenue beats on services business boost
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bombardier's quarterly revenue beats on services business boost
Nov 9, 2024 12:00 PM

(Reuters) -Bombardier's third-quarter revenue beat analysts' estimates on Thursday, helped by strong demand for business jet parts and repairs.

Business jet makers are increasing their order backlogs as they benefit from a wave of interest from wealthy travellers that has continued since the COVID-19 pandemic.

Despite an 18-day strike in July at one of its Canadian facilities, Bombardier delivered 30 jets during the third quarter ending September, compared with 31 aircraft a year earlier.

The Challenger jet maker reported cash burn, a metric closely watched by investors, of $127 million during the quarter, compared with a positive cash flow of $80 million in the same period last year.

Bombardier maintained its full year forecast for jet deliveries of 150 to 155 aircraft.

Revenue from the company's services business rose 28% in the third quarter to $528 million.

Montreal-based Bombardier's total revenue for the quarter was $2.07 billion, compared with the average analyst estimate of $1.79 billion, according to data compiled by LSEG.

On an adjusted basis, the company earned 74 cents per share, compared with estimates of 73 cents.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
Jun 6, 2024
08:14 AM EDT, 06/06/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was superior to investigational bulevirtide 10 mg monotherapy for the treatment of compensated chronic hepatitis delta virus infection. The company is evaluating the efficacy and safety of bulevirtide as monotherapy...
Update: FAA Extends Cuts to Minimum Flight Requirements in New York Amid Traffic Controller Shortage
Update: FAA Extends Cuts to Minimum Flight Requirements in New York Amid Traffic Controller Shortage
Jun 6, 2024
08:12 AM EDT, 06/06/2024 (MT Newswires) -- (Updates with details from FAA's statement.) The Federal Aviation Administration said Wednesday it is further extending a waiver of minimum flight requirements at congested New York City-area airports through October 2025. The number of air traffic controllers is insufficient in New York for normal traffic levels, and increasing flexibility is needed to avoid...
Moderna Says US FDA Selects Rare Genetic Disorder Therapy for Pilot Program
Moderna Says US FDA Selects Rare Genetic Disorder Therapy for Pilot Program
Jun 6, 2024
08:13 AM EDT, 06/06/2024 (MT Newswires) -- Moderna ( MRNA ) said Thursday that the US Food and Drug Administration has selected its experimental therapy, mRNA-3705, to treat methylmalonic acidemia, a rare genetic disorder, for a pilot program aimed at supporting clinical trials to advance rare disease therapeutics. Selection for this program will enable enhanced communication with the US FDA,...
BRIEF-Cycle Pharmaceuticals Announces All-Cash Proposal To Acquire Vanda Pharmaceuticals For $8.00 Per Share
BRIEF-Cycle Pharmaceuticals Announces All-Cash Proposal To Acquire Vanda Pharmaceuticals For $8.00 Per Share
Jun 6, 2024
June 6 (Reuters) - Vanda Pharmaceuticals Inc ( VNDA ): * CYCLE PHARMACEUTICALS ANNOUNCES ALL-CASH PROPOSAL TO ACQUIRE VANDA PHARMACEUTICALS FOR $8.00 PER SHARE * CYCLE PHARMACEUTICALS LTD: PROPOSED DEAL REPRESENTING A TOTAL CASH CONSIDERATION OF $466 MILLION Source text for Eikon: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved